Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Further details about the exact facilities that will receive the investment weren't disclosed ... AstraZeneca also ...

威斯康星州麦迪逊 - 以癌症筛查和诊断测试而闻名的Exact Sciences Corp. (NASDAQ: EXAS)公布了研究结果，显示多癌症早期检测 (MCED)测试取得进展。在圣地亚哥举行的美国癌症研究协会特别会议上展示的研究表明，一种新的多生物标志物方法可以提高癌症检测率，尤其是在早期阶段。

威斯康星州麦迪逊市—Exact Sciences Corp (NASDAQ:EXAS)总裁兼首席执行官Kevin Conroy近期大量购入公司普通股。根据最新的SEC文件显示，Conroy于11月13日以每股51.35美元的价格购入19,500股，总投资额为1,001,325美元。 此次交易使Conroy的直接持股增加到1,074,191股。此外，他还通过退休和信托账户间接持有公司股票，以及683 ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.